Standard information requirements

To meet your registration obligations, you must fulfil the minimum standard information requirements set by REACH. These requirements depend on the volume of the substance you manufacture or import into the EU/EEA.


Identify the relevant information requirements for your substance
  • Follow the general information requirements for all registrants, including those that cover your substance identification, which are described in Annex VI to REACH.
  • Follow the specific hazard information requirements relevant for the different tonnage bands outlined in Annexes VII-X to REACH. Note that the higher the volume, the more information is required.
  • Keep in mind that, in some cases, you may need information relevant for higher tonnages to ensure the safe use of your substance, for example, if it has mutagenic properties.


Physicochemical properties:
  • Perform all new tests for physicochemical hazards according to the methods referred to in the CLP Regulation, and in compliance with a recognised quality system or by laboratories complying with a relevant recognised standard. This ensures that the results are adequate for classification and labelling under CLP and follow the United Nations Recommendations on the Transport of Dangerous Goods, Manual of Tests and Criteria.
  • Some physicochemical properties are interlinked with other information requirements. Make sure that information included in different parts of your dossier is consistent and explain any unexpected findings.


Toxicological properties:
  • REACH annexes are sequential. Therefore, Annex VII requirements (e.g. for in vitro irritation testing) should be fulfilled before considering Annex VIII requirements (e.g. in vivo testing). However, there are some cases where you may perform an Annex VIII test to also fulfil an Annex VII requirement. For example, if your substance does not exert toxic effects, you can first perform the 28-day repeated-dose toxicity (Annex VIII) study and use the results within a weight-of-evidence approach to fulfil the acute oral toxicity endpoint (Annex VII).
  • If you need new data for skin and eye irritation, or for skin sensitisation, you must always start with in vitro tests, regardless of the annual tonnage of the substance.


  • If you get a positive result in one in vitro experiment, you must follow it up with an in vivo study. However, you must submit a testing proposal before mutagenicity testing on vertebrate animals can start. If you do not consider an in vivo follow-up test to be necessary, you must provide a scientifically-sound and well-documented adaptation with appropriate justification in your dossier.
  • You need to perform a study combining a comet assay (OECD Test Guideline 489) and a micronucleus test (OECD TG 474) if:
    • concerns for both gene mutation and chromosomal aberration exist; and
    • there is no other in vivo genotoxicity data available.
    The combination can help to reduce the number of tests performed and the number of animals used while providing useful information on the potential of the substance to induce chromosomal aberration or gene mutation in vivo. This approach applies to compliance checks and testing proposal examinations under REACH Annexes VIII, IX and X.
  • You may need to carry out a germ cell genotoxicity study (OECD TG 488 or OECD TG 483) for substances manufactured or imported at 100 tonnes per year or more (Annexes IX or X to REACH) if:
    • an in vivo genotoxicity test on somatic cell is positive; and
    • no clear conclusion can be made on germ cell mutagenicity.


Reproductive toxicity:
  • A screening study (OECD TG 421 or OECD TG 422), required under Annex VIII, does not fulfil the information requirement for a sub-chronic toxicity study (90-days, OECD TG 408), nor for a pre-natal developmental toxicity study (OECD TG 414) or an extended one-generation reproductive toxicity study (OECD TG 443).
  • To meet the standard information requirements for a substance registered for 1 000 tonnes or more per year (Annex X), you need to perform a pre-natal developmental toxicity studies (OECD TG 414) on two species. According to OECD TG 414, rats are the preferred rodent species and rabbits are the preferred non-rodent species. If you consider another species to be more relevant, provide a justification.
  • Have a look at ECHA’s technical report on how it identifies and concludes on the design of the extended one-generation reproductive toxicity study (EOGRTS). You will find crucial information sources for defining the EOGRTS design and triggering the study itself.


Environmental fate and pathways:
  • In biodegradation studies, make sure that the microbial inoculum is not adapted, as this is not accepted. Adaptation of microbial inoculum means that inoculum is in contact with the tested substance before initiating the biodegradation test. Aeration and washing with mineral media are not regarded as inoculum adaptation.
  • Identify degradation products and report them accordingly. Information on degradation products is generally obtained from simulation tests. Conduct additional testing for these products if they can pose a risk or are expected to be of otherwise high concern, e.g. persistent, bioaccumulative and toxic (PBT); or very persistent and very bioaccumulative (vPvB).
  • Use the recommended test guidelines OECD TG 307, OECD TG 308 and OECD TG 309 for simulation testing for water, soil and sediment. Sewage treatment plant (STP) simulation tests (e.g. OECD TG 303 or OECD TG 314) are not appropriate as a sole source of information to conclude if a substance fulfils the persistent/very persistent criteria.
  • When assessing persistency and bioaccumulation for PBT/vPvB assessment needs, you should also consider each constituent, impurity or additive present in a concentration at or above 0.1 % weight by weight (w/w) or, if not technically feasible, in concentrations as low as technically quantifiable. Also consider any relevant degradation/transformation products, i.e. at least those detected at ≥10 % of the applied dose at any sampling time or those that are continuously increasing during the study even if their concentrations do not exceed 10 % of the applied dose, as this may indicate persistence. Alternatively, justify why these are not relevant for the PBT/vPvB assessment.
  • The formation of non-extractable residues (NERs) may be significant in the simulation tests in surface water, sediment and soil. By default, total NER is regarded as a non-degraded substance. However, if reasonably justified and analytically demonstrated, a certain part of NERs may be differentiated and quantified as irreversibly bound or as degraded to biogenic NERs, such fractions could be regarded as removed when calculating the degradation half-lifes (ECHA Guidance R. Therefore, quantify the NERs formed in the simulation tests in surface water, sediment and soil, and report results including a scientific justification of the used extraction procedures and solvents.
  • Bioaccumulation in fish aqueous and dietary exposure (Method EU C.13 / OECD TG 305) is the preferred test for bioaccumulation. You must conduct a test for exposure via the aqueous route (OECD TG 305-I) unless it can be demonstrated that it is not technically possible. If you justify and document that testing through aquatic exposure is not technically possible, you may conduct a study using the dietary exposure route (OECD 305-III).


Ecotoxicological properties:
  • Use the recommended fish early-life stage (FELS) toxicity test (OECD TG 210) to examine long-term fish toxicity. The test covers several life stages of the fish from the newly fertilised egg, through to its hatch and early stages of growth, and is appropriate for examining the potential toxic effects of substances expected to cause effects over a longer exposure period, or which require a longer time to reach a steady state.
  • OECD TG 204 (Fish, Prolonged Toxicity Test: 14-day study) cannot be considered as a suitable long-term test. This study is regarded as a prolonged toxicity study with fish mortality as the major endpoint examined.
  • When deciding on a testing strategy for aquatic toxicity of the substance, the information on acute aquatic toxicity is essential for aquatic classification under CLP and, more specifically, for deriving the M factor. The CLP includes both acute and chronic hazard categories for the aquatic environment and you must assess both when addressing this hazard class.
  • Use the equilibrium partitioning method (EPM) to predict toxicity to terrestrial organisms only when effects are observed in the aquatic toxicity tests. If a substance does not show effects in the aquatic toxicity tests, this method cannot be used.
  • The intrinsic properties of chemicals on soil microbial communities are not addressed through the EPM extrapolation method and therefore the potential adaptation possibility outlined for the information requirement of Annex IX, Section 9.4. does not apply for the information requirement under Annex IX, section 9.4.2. The nitrogen transformation test (OECD TG 216) is considered sufficient to fulfil the information requirement of effects on soil micro-organisms (Annex IX, Section 9.4.2.) for most non-agrochemicals. For agrochemicals, OECD TG 217 is also needed.
  • For substances that have a high potential to adsorb to soil or that are very persistent (with a Log Kow >5 or a DT50 >180 days or, in the absence of DT50 the substance is considered not readily biodegradable), you need to perform a long-term terrestrial toxicity test according to Annex X instead of carrying out short-term testing, even if the substance is registered under Annex IX (100-1 000 tonnes per year).


Issues related to study design:
  • Provide adequate information on the physicochemical and fate properties of the test material. If required, follow the specific requirements for substances that are difficult to test (OECD Guidance Document No.23 on Aqueous-phase on Aquatic Toxicity Testing of Difficult Chemicals).
  • For all aquatic studies, always provide a reliable analytical monitoring of exposure concentrations.
  • For some substances, it may be difficult to achieve and maintain the desired exposure concentrations. Therefore, you must monitor the test concentrations of your substance throughout the exposure duration and report the results. If it is not possible to demonstrate the stability of exposure concentrations, i.e. measured concentrations are not within 80-120 % of the nominal concentrations, you must report the effect concentration based on measured values.
  • For multi-constituent or UVCB substances that contain constituents with different properties, e.g. a wide range of water solubilities, use one of the appropriate techniques for aquatic toxicity testing described in the OECD Guidance Document No. 23.


Adaptation of long-term aquatic toxicity testing under Annex IX to REACH:
  • You may be required to perform longer term fish toxicity tests that go beyond those described in Annex IX, column 1. This is based on the Board of Appeal’s decision (A-011-2018) from 4 May 2020 stating that REACH Annex IX (section 9.1, column 2) does not allow registrants to omit information on long term toxicity to fish under column 1. Following the Board of Appeal’s decision of 4 May 2020 on appeal case A-011-2018, Annex IX, Section 9.1, Column 2 to REACH does not allow registrants to omit submitting information on long term toxicity to fish under Column 1. Instead, it must be understood as a trigger for providing further information on long-term aquatic toxicity if the chemical safety assessment according to Annex I indicates such a need. In practice, this means that further long-term fish toxicity tests than those described in Annex IX, column 1, may be required depending on the properties of the substance
  • In situations where exposure is absent or so low that additional hazard information will not lead to improved risk management, you may use an exposure-based adaptation (Annex XI, Section 3; ECHA Guidance R.5). Remember to clearly define and justify the legal basis for such an adaptation, i.e. Annex XI, Section 3.2(a) and/or (b) and/or (c). Registrants must provide adequate justification and documentation based on a thorough and rigorous exposure assessment in accordance with Section 5 of Annex I to REACH and must meet the criteria specified for the type of exposure-based adaptation that is being claimed. All stages of the life cycle of the substance must be considered in the justification (including article service-life, if relevant, and the waste stage).
  • The Board of Appeal decision on case A-011-2018 overrides advice given in the ECHA Guidance. This means that the as a consequence, information on aquatic toxicity described in ECHA’s Guidance on Information Requirements and Chemical Safety Assessment related to REACH Annex IX, section 9.1, Column 2 as a waiver for the information requirement under Column 1 is no longer valid.

Categories Display

Tagged as:

(click the tag to search for relevant content)